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Introduction
Multiple sclerosis (MS) is a chronic inflammatory 
disease of the central nervous system that most 
frequently strikes young women.1 In the past 5 
years, therapeutic options for treating relapsing 
remitting MS (RRMS) have impressively broad-
ened and new oral first-line agents have been 
approved.2,3 In European countries, delayed-
release dimethyl fumarate (DMF), also known as 
gastro-resistant DMF, and teriflunomide (TRF) 
are used in the treatment of persons with RRMS 
(pwRRMS).3 Pivotal trials have demonstrated the 
benefits of DMF and TRF on both clinical symp-
toms (i.e. number of clinical relapses and disabil-
ity accrual) and on magnetic resonance imaging 
(MRI) disease activity, with a generally good 
tolerability.4–8
No head-to-head clinical trials have compared the 
efficacy of DMF versus TRF, although a recent 
number needed to treat (NNT) analysis compar-
ing outcomes from pivotal studies of DMF, TRF, 
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Abstract
Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease 
activity’ (NEDA) over a 12-month period in a large multicenter population with relapsing 
remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) 
and teriflunomide (TRF) using a propensity-score adjustment.
Methods: A time-to-event method was used to determine the percentages of patients with 
RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed 
disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the 
safety profile of the investigated drugs.
Results: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS treated with TRF, 468 
pwRRMS were successfully paired by propensity score: 234 on DMF and 234 on TRF. The 
percentages of pwRRMS who achieved NEDA 3 were 80.3% in the DMF group and 77.2% in 
the TRF group. Serious adverse events occurred in four (1.9%) pwRRMS on DMF and in three 
(1.3%) pwRRMS on TRF.
Conclusions: DMF and TRF significantly impacted RRMS disease activity in our study. Serious 
safety concerns were recorded in less than 2% of the studied population.
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and fingolimod showed that the NNT for key clin-
ical outcomes was similar in the three agents.9–11
In recent years, there has been growing interest in 
performing high-quality observational cohort 
studies to collect longitudinal information that is 
representative of real MS clinical practice, reveal-
ing data highly concordant with the evidence 
obtained from clinical trials.9–11
In this study, we explored the practical utility, 
efficacy, and safety profile of DMF and TRF over 
12 months in a large multicenter population of 
pwRRMS.
Our main outcome was the proportion of pwR-
RMS with no evidence of disease activity (NEDA) 
defined as the absence of relapses, progression of 
disability, and worsening radiographic findings 
(NEDA 3).
Methods
This was an independent, multicenter, prospec-
tive, observational study conducted in a large 
Italian population of pwRRMS treated with two 
oral first-line drugs, DMF and TRF.
All pwRRMS included in the study were treated 
in accordance with the approved label instruc-
tions and the expected standards of good clinical 
practice. Written informed consents were col-
lected. Treatment protocols, which involved 
DMF (120 mg twice per day for the first 7 days, 
then 240 mg twice per day), and TRF (14 mg 
once per day), are described elsewhere.12,13
Complementary clinical, radiographic (brain 
MRI lesions), and demographic parameters were 
acquired retrospectively, up to 12 months before 
the treatments started.
Data were recorded as part of routine clinical prac-
tice at each tertiary participating MS center, with 
data entry performed at the time of clinical visits. 
The data entry portal was iMED© software and we 
followed a rigorous quality assurance procedure.14
pwRRMS were consecutively included in the 
study at the initiation of DMF or TRF treatment 
(baseline) and were monitored over 12 months, 
with data collection performed at baseline and 
after 12 months following drug initiation. Data 
were censored at the last follow-up visit.
This study was approved by the Azienda 
Ospedaliero Universitaria Policlinico Vittorio 
Emanuele (Catania, Italy) Ethics Committee 
(n.177/2017/PO).
This study received no financial support for the 
design, data collection, data analysis, data inter-
pretation, or writing.
The corresponding author had full access to the 
entire database and had the final responsibility of 
submitting this manuscript.
Key eligibility criteria included: (a) age 18 years 
or older; (b) a diagnosis of RRMS according to 
the McDonald criteria;15 (c) a disability score at 
enrollment (assessed by the Expanded Disability 
Status Scale [EDSS])16 of no more than 3.5 
(selected to exclude any patients with severe MS); 
(d) initiating one of the study therapies in the 
index enrollment window (1 January 2015–1 
March 2016) to allow for at least 12 months of 
follow up; (e) no history of stem-cell transplanta-
tion; (f) no ongoing participation in randomized 
clinical trials.
For all enrolled patients, the following clinical 
and demographic variables were collected: sex, 
age, time of first MS symptom, dates of clinical 
relapses, and disability score assessed by EDSS at 
commencement of treatment (within 12 months 
of the start of treatment).
Disability was assessed by Neurostatus-certified 
MS specialists; any EDSS score recorded within 
30 days of a previous relapse was excluded, as 
described elsewhere.
All pwRRMS willing to authorize the release of 
their coded medical information to iMED© 
software signed a consent form. The signed 
consent form had to be filed in the individual’s 
MS clinic chart and a copy made available to the 
pwRRMS.
Outcomes
The primary outcome of the study was to evaluate 
the proportion of pwRRMS with no evidence of 
disease activity, as defined by NEDA 3, during 
the 12-month observational period.
NEDA 3 was defined as a composite that con-
sisted of: (a) the absence of clinical relapses; (b) no 
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confirmed disability progression sustained for 12 
weeks (as measured by EDSS); (c) the absence of 
T1 gadolinium-enhancing (Gad+) brain lesions 
as well as the absence of any new/newly enlarging 
T2 brain lesions.
A relapse was defined as the occurrence of new 
symptom(s) or the exacerbation of existing 
symptom(s) persisting for at least 24 h in the 
absence of concurrent illness or fever, occurring 
at least 30 days after a previous relapse.17
Confirmed disability progression was defined as 
an increase in EDSS ⩾ 1.0 point from the base-
line EDSS, sustained for 12 weeks or longer. The 
number of brain MRI lesions on T2, T1, and T1 
Gad+ was recorded during the 12-month period 
before treatment initiation and the 12-month fol-
low-up period.
The secondary outcome was the time of the new 
first clinical relapse within 12 months.
We collected data to evaluate the real-life safety 
and tolerability of the two drugs. We examined 
the frequency of adverse events (AEs) and the 
proportion of severe AEs (using the European 
Medical Agency’s definitions of AE and serious 
adverse event [SAE]). We considered an AE to be 
any untoward medical occurrence in a subject 
who had been administered a pharmaceutical 
product, but without a necessary causal relation-
ship with the treatment.18
An SAE was any AE that resulted in: death, a life-
threatening AE, inpatient hospitalization or prolon-
gation of existing hospitalization, a persistent or 
significant incapacitation or substantial disruption 
of the ability to conduct normal life functions, a 
congenital anomaly/birth defect, or any events that 
may require medical or surgical intervention to pre-
vent one of the outcomes listed in this definition.
Lymphopenia was defined according to the 
Common Terminology Criteria for Adverse 
Events definition as a laboratory result indicating 
a decrease in the number of lymphocytes in a 
blood specimen. In pwRRMS, it is considered 
notable when the value drops below 200/mm3.19
Statistical analysis
All patients’ characteristics were reported as fre-
quencies (%) for categorical variables and mean 
± standard deviation (SD) or median with inter-
quartile range for continuous variables. 
Comparisons of baseline characteristics prior to 
propensity-score matching between the treatment 
arms were performed using the Wilcoxon rank 
sum test or the chi-square test, depending on the 
nature of the variables.
A paired-matched analysis of the two treatments 
was conducted. The pwRRMS in the DMF group 
were matched to patients in the TRF group on the 
basis of propensity scores calculated using a mul-
tivariable logistic regression. All of the following 
were used in the regression analysis as independ-
ent variables: age, sex, disease duration, prestudy 
EDSS scores (measured at 24 months, 12 months, 
and 6 months), the disease-modifying therapies 
(DMTs) administered before the beginning of the 
study (considering both first-line and second-line 
therapies), and the reason for switching. A 1:1 
nearest neighbor matching without replacement 
was used. The postmatch balance was confirmed 
by evaluating the standardized mean differences.
The comparison of some outcome variables of 
interest was carried out with standard tests. 
Survival analyses were conducted using the 
Kaplan–Meier method to estimate the time to 
relapse within 12 months of treatment, and the 
differences between the two groups of interest 
were estimated by the logrank test. Results were 
expressed both as medians and hazard ratios 
(HR) with corresponding 95% confidence inter-
vals. Statistical significance was achieved at a p 
value of < 0.05.
The study power was 0.90 (alpha 0.05); null 
hypothesis: expected NEDA 3 in study drugs 
75% ± 15%.
All analyses were performed using the Statistical 
Analysis System (SAS Institute, Release 9.4), the 
R package (version 3.3.0), and SPSS version 21 
(IBM SPSS Statistics 21, IBM, Armonk, NY, 
USA).
Results
From a total sample of more than 6000 pwRRMS 
from nine Italian centers, 903 were considered 
eligible for analyses. Of those, 587 pwRRMS 
treated with DMF and 316 pwRRMS treated 
with TRF met the inclusion criteria and were 
included in this study (Figure 1).
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Table 1 shows the comparison of patients’ base-
line characteristics before matching. pwRRMS on 
TRF were older than pwRRMS on DMF 
(p < 0.0001). The gender ratio was also different 
with a predominance of women in the DMF 
group (p < 0.05).
We observed that the TRF group had a longer 
disease duration (⩾ 96 months) than the DMF 
group (p < 0.05). Furthermore, there were more 
pwRRMS who had not been previously treated 
with DMTs in the DMF group compared with 
the TRF group (p < 0.005). In the two groups, 
about 54.5% and 51.2% of pwRRMS had been 
previously treated with first-line therapies; poor 
tolerability was the most frequent reason for 
switching (50% and 51.3%, respectively).
The TRF group showed a higher level of disabil-
ity (EDSS range [min–max] 1.5–3.5 versus 1.0–
3.0 for DMF) (p < 0.0001).
The matching procedure improved the balance 
between the compared groups: no differences in 
the demographic and clinical characteristics were 
observed after applying the propensity score 
(Table 2).
The SD for all postmatching characteristics was 
lower than 0.4. The results of the output variables 
comparison analysis are shown in Table 3.
The NEDA 3 status at 12 months showed no dif-
ferences between the two groups: 188 (80.3%) 
pwRRMS in the DMF group and 181 (77.2%) 
pwRRMS in the TRF group met the NEDA 3 
criteria (Figure 2). Figure 2 shows that there were 
no differences between the two groups in the pro-
portion of pwRRMS with NEDA 3 status for all 
three individual measures (i.e. new relapses, 
EDSS progression, new MRI lesions) after 12 
months of follow up. The Kaplan–Meier survival 
curves showed no difference between the two 
Figure 1. Flow chart of the study. DMF, dimethyl fumarate; PS, propensity score; pwRRMS, patients with 
relapsing remitting multiple sclerosis; TRF, teriflunomide.
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Table 1. Comparison of baseline characteristics between the two treatment groups prior to propensity-score 
matching.
Variable DMF TRF p value*
No. Group 587 316
Age, mean (SD) 38.6 (10.9) 46.3 (10.3) < 0.001
Sex, No. (%)
 Female 416 (70.9) 199 (63) 0.01
 Male 171 (29.1) 117 (36)  
Disease duration (months), mean (SD) 103.6 (82.6) 115.7 (86) 0.03
Reasons switch to study drugs, No. (%)
 Naïve 168 (28.6) 70 (22.2) < 0.001
 Tolerability 294 (50) 162 (51.3)  
 Lack of efficacy 125 (21.3) 84 (26.6)  
Line of therapy pre-switch, No. (%)
 Naïve 168 (28.6) 70 (22.2) < 0.001
 First line 320 (54.5) 153 (51.2)  
 Second line 99 (16.9) 84 (26.6)  
Time on DMT pre-switch (months), mean (SD) 36.6 (38.4) 38.6 (45.6) 0.68
Relapses 24 months before switch, mean (SD) 0.9 (1.2) 0.8 (1) 0.11
Relapses 12 months before switch, mean (SD) 0.7 (0.8) 0.6 (0.7) 0.34
EDSS 12 months before switch 1.5 (1–3) 2 (1.5–3.5) < 0.001
EDSS 6 months before switch 1.5 (1–3) 2 (1.5–3.5) < 0.001
MRI T1 24 months before switch, mean (SD) 4.4 (8.9) 3.2 (6) 0.84
MRI T1 12 months before switch, mean (SD) 4.5 (9) 3.6 (7.5) 0.48
MRI T2 24 months before switch, mean (SD) 14.9 (31.6) 13.1 (30.6) 0.51
MRI T2 12 months before switch, mean (SD) 15 (21.9) 12 (16.4) 0.49
MRI Gad+ 12 months before switch, mean (SD) 0.5 (1) 0.4 (1.2) 0.10
MRI Gad+ 24 months before switch, mean (SD) 0.2 (0.7) 0.3 (0.7) 0.78
Results are expressed as mean (SD), median (IQR), and No. (%). *Differences were evaluated via the Wilcoxon rank sum 
test or the chi-square test.
DMF, dimethyl fumarate; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; Gad+, gadolinium; 
IQR, interquartile range; MRI, magnetic resonance imaging; SD, standard deviation; TRF, teriflunomide.
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Table 2. Baseline characteristics of propensity score-matched patients.
Variable DMF TRF SD*
No. Group 234 234  
Age, mean (SD) 45.7 (9.9) 44.9 (9.2) 0.12
Sex, No. (%)
Female 148 (63.3) 151 (64.5) 0.01
Male 86 (36.8) 83 (35.5)  
Disease duration (months), mean (SD) 124.4 (85) 125.8 (85.5) 0.03
Reasons for switch to oral drug, No. (%)
 Naïve 24 (10.3) 25 (10.7) 0.10
 Tolerability 144 (61.5) 162 (69.2)  
 Lack of efficacy 66 (28.2) 47 (20)  
Line of therapy pre-switch, No. (%)
 Naïve 24 (10.3) 25 (10.7) 0.10
 First line 144 (61.5) 162 (69.2)  
 Second line 66 (28.2) 47 (20)  
Time on DMT pre-switch (months), mean (SD) 42 (44.4) 46.8 (42) 0.11
Relapses 24 months before switch, mean (SD) 0.8 (1) 0.9 (1.2) 0.12
Relapses 12 months before switch, mean (SD) 0.6 (0.7) 0.6 (0.8) 0.08
EDSS 24 months before switch, median (IQR) 2.5 (1.5–3.5) 2 (1.5–3.5) 0.05
EDSS 12 months before switch, median (IQR) 2.5 (1.5–3.5) 2 (1.5–3.5) 0.05
EDSS 6 months before switch, median (IQR) 2.5 (1.5–3.5) 2 (1.5–3.5) 0.04
MRI T1 24 months before switch, mean (SD) 3.2 (6.3) 6.5 (11) 0.35
MRI T1 12 months before switch, mean (SD) 3.7 (8) 6.6 (11.9) 0.28
MRI T2 24 months before switch, mean (SD) 13.4 (32.9) 19.9 (39.5) 0.15
MRI T2 12 months before switch, mean (SD) 12 (17.2) 18.8 (25.6) 0.29
MRI Gad+ 24 months before switch, mean (SD) 0.4 (1) 0.36 (1) 0.06
MRI Gad+ 12 months before switch, mean (SD) 0.3 (0.6) 0.2 (0.4) 0.17
*Differences were evaluated via the standardized differences (SD). Standardized differences of 0.2, 0.5, and 0.8 represent 
small, medium, and large differences, respectively. Results are expressed as mean (SD), median (IQR), and No. (%).
DMF, dimethyl fumarate; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; Gad+, gadolinium; 
IQR, interquartile range; MRI, magnetic resonance imaging; SD, standard deviation; TRF, teriflunomide.
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groups in the time to reach the first relapse after 
12 months of treatment (Figure 3). Among all 
pwRRMS, 10 (4.3%) in the DMF and 7 (3%) in 
the TRF group discontinued the study drugs. 
The reasons for drug discontinuation included a 
lack of efficacy for six pwRRMS on DMF and for 
two pwRRMS on TRF; this finding was not sta-
tistically significant.
Safety
The percentage of pwRRMS who experienced 
any AE was 26.5% in the DMF group and 12% in 
the TRF group (p < 0.001). The rate of SAEs 
was similar between the two groups: 1.3% in 
the DMF group and 1.9% in the TRF group 
(Tables 4 and 5). An AE was the reason for drug 
discontinuation in four pwRRMS on DMF and 
Table 3. Comparison of output variables between the two groups.
Variable DMF TRF SD*
No. Group No. Group 234 234
NEDA 3, No. (%)
 No disease activity 181 (77.2) 188 (80.3) 0.42
 Disease activity 53 (22.6) 46 (19.7)  
NEDA-relapse, No. (%)
 No disease activity 209 (89.3) 210 (89.7) 0.87
 Disease activity 25 (10.7) 24 (10.3)  
NEDA-EDSS, No. (%)
 No disease activity 219 (93.6) 216 (92.3) 0.29
 Disease activity 15 (6.4) 18 (7.7)  
NEDA-MRI, No. (%)
 No disease activity 210 (89.7) 216 (92.3) 0.94
 Disease activity 24 (10.3) 18 (7.7)  
pw relapses12 months post beginning study drugs, No. (%) 29 (10.7) 28 (10.3) 0.88
EDSS 6 months post beginning study drug, median (IQR) 2 (1.5–3.5) 2 (1.5–3.5) 0.42
EDSS 12 months post treatment, median (IQR) 1.5 (1.5–3.5) 2 (1.5–3.5) 0.28
pw with new T2 lesions 12 months post beginning study drugs, No. (%) 17 (7.3) 13 (5.6) 0.12
pw with new T1 Gad+ lesions post beginning study drugs, No. (%) 7 (3) 5 (2.1) 0.55
MRI T1 12 months post treatment, mean (SD) 2.4 (4.9) 7 (11) 0.10
MRI T2 12 months post treatment, mean (SD) 7.2 (14.2) 10.8 (22.9) 0.04
MRI Gad+ 12 months post treatment, mean (SD) 0.1 (0.5) 0.3 (1.2) 0.29
pw who stopped study drugs, No. (%) 10 (4.3) 7 (3) 0.45
Safety alerts, No. (%) 62 (26.5) 28 (12) < 0.001
*Differences were evaluated via the Wilcoxon rank sum test or the chi-square test.
Results are expressed as mean (SD), median (IQR) and No. (%).
DMF, dimethyl fumarate; EDSS, Expanded Disability Status Scale; Gad+, gadolinium; IQR, interquartile range; MRI, magnetic resonance imaging; 
NEDA, no evidence of disease activity; pw, persons with; SD, standard deviation; TRF, teriflunomide.
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in three pwRRMS on TRF. Two pwRRMS on 
TRF stopped therapy for pregnancy and an accel-
erated elimination procedure with cholestyramine 
was initiated (Figure 4).20 The cancers observed 
during the study period included thyroid cancer 
and melanoma. A medical multidisciplinary team 
concluded that the cancers were not related to the 
investigation drug. No pregnancies occurred dur-
ing the observation period.
Discussion
In our population, the treatment with TRF and 
DMF resulted in the control of disease activity 
(assessed by NEDA 3 and time to the new first 
clinical relapse) at 12 months of follow up. DMF 
and TRF are licensed as first-line therapy options 
in RRMS; their approval has changed the treat-
ment of early RRMS. In pivotal trials, both 
showed similar efficacy in controlling the clinical 
Figure 3. Time to first relapse within 12 months in the two groups.
DF, degrees of freedom; DMF, dimethyl fumarate; TRF, teriflunomide.
Table 4. Frequency distribution of more common adverse events and serious adverse events in persons with 
relapsing remitting multiple sclerosis treated with dimethyl fumarate.
Dimethyl fumarate 62 (26.5), No. (%)
Adverse events Flushing, itch 31 (13.3)
Diarrhea, colitis 11 (5.6)
Epigastralgia, nausea 9 (3.8)
Lymphopenia 3 (2.1)
Increase of transaminases 2 (0.9)
Herpes zoster reactivation 1 (0.4)
Depression 1 (0.4)
Serious adverse events Severe lymphopenia 2 (0.9)
Severe diarrhea 2 (0.9)
Therapeutic Advances in Neurological Disorders 11
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and MRI disease activity of RRMS with a gener-
ally good tolerability and safety profile.4–7,21
No head-to-head clinical trials have compared 
the efficacy of DMF versus TRF as measured by 
NEDA.
A recent multicomparative analysis of MS out-
comes in pwRRMS treated with DMF com-
pared with propensity-matched fingolimod, 
interferon, glatiramer acetate, and TRF treated 
patients showed that DMF resulted in a similar 
risk of experiencing a new relapse to that of a 
matched cohort of fingolimod-treated patients. 
Conversely, DMF was associated with a statis-
tically significant reduction in risk of relapse 
relative to interferon, glatiramer acetate, and 
TRF.22
Similarly, at the American Academy of 
Neurology’s 2017 meeting, no difference in risk 
of relapse between fingolimod and DMF was 
described (HR 0.995; p = 0.94), while TRF was 
associated with a significantly higher risk of expe-
riencing relapse (HR 1.302; p < 0.01). Similar 
findings were observed in the subgroups stratified 
by receipt of DMTs in the prior year (newly 
treated patients versus patients previously treated 
with a different agent). The results were adjusted 
for demographics, baseline comorbidities, MS 
symptoms, prior DMT use, and pre-enrollment 
annualized relapse rate.23
Finally, a comparative effectiveness research 
analysis from a large health insurance claims 
database was performed to estimate the relative 
risk of relapse between MS patients treated with 
fingolimod or TRF compared with DMF after 
adjusting for demographics, baseline comorbidi-
ties, MS symptoms, prior MS drug use, and pre-
index annualized relapse rate. It showed that 
TRF was associated with a 30% (HR 1.302; 
p < 0.01) increase in relative risk of MS relapse 
compared with DMF.9
In summary, our data are informative regarding 
treatment decisions in pwRRMS. Prior to match-
ing, the data showed that the proportion of men 
and older patients was greater in the TRF group 
than in the DMF group. This may reflect Italian 
clinical practice pattern, and the concern about 
prescribing TRF to women of childbearing poten-
tial. Recent data on the outcomes of 83 pregnan-
cies among TRF-treated women are mitigating 
such concerns.24
Interestingly, more than 50% of pwRRMS in our 
population had experienced another treatment 
prior to the initiation of DMF or TRF. This may 
reflect the rapid shift from injectables (due to 
Table 5. Frequency distribution of more common adverse events and serious adverse events in persons with 
relapsing remitting multiple sclerosis treated with terifluonomide.
Terifluonomide 28 (12), No. (%)
Adverse events Arterial hypertension 6 (2.6)
Transaminases elevation 5 (2.1)
Alopecia 4 (1.7)
Nausea, vomiting 3 (1.3)
Neuropathy 2 (1.7)
Lymphopenia 2 (0.9)
Epstein–Barr virus reactivation 1 (0.4)
Flushing 1 (0.4)
Articular pain 1 (0.4)
Serious adverse events Cancers 2 (0.9)
Severe vomiting 1 (0.4)
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AEs, poorer compliance, and the unwillingness of 
pwRRMS to undergo injections) upon the intro-
duction of oral agents in Italy.
The majority of pwRRMS in our study had mild 
functional disability (EDSS < 3.0). The disability 
levels of our pwRRMS mirror those populations 
enrolled in the pivotal trials of the investigated 
drugs. Moreover, in Italian clinical practice, pwR-
RMS with highly active disease and with worsen-
ing disability are usually stratified to second-line 
therapies such as fingolimod, natalizumab, or 
alemtuzumab.
After the propensity-score adjustment, the data 
showed the efficacy of DMF and TRF in impact-
ing RRMS activity.
Recent postmarketing studies have investigated 
the efficacy and safety of DMF and TRF in 
RRMS.25–27 An observational study performed in 
Kuwait which evaluated 119 pwRRMS on DMF 
found 89.9% of pwRRMS to be free from 
relapses, 85% of pwRRMS to be free from new 
brain MRI findings, and 93% of pwRRMS to be 
free from disability accrual (assessed by EDSS) 
after a mean observational period of 20 months. 
No composite measure such as NEDA was 
evaluated.28
A recent retrospective study examining 102 pwR-
RMS treated with TRF showed that approxi-
mately 10% of pwRRMS experienced relapses 
during the treatment period; 40% of these relapses 
occurred during the first 6 months of therapy. Of 
74 pwRRMS treated with TRF, the EDSS 
remained constant in approximately 67% of this 
population during 15 (±5.3) months of follow 
up. Of 30 pwRRMS treated with TRF, 47% of 
pwRRMS experienced new T2 brain lesions on 
MRI.29
In our study, pwRRMS on TRF experienced 
more progression of MRI activity than those 
treated with DMF at the time of follow up. A cor-
relation between MRI T2 lesion load and MS dis-
ease duration and disability level has previously 
been described.
One limitation to our study was the relatively short 
follow-up period. Detecting significant changes in 
EDSS during this short period is challenging, due 
to the intrinsic bias of such outcomes measure.30 
Therefore, our findings on disability accrual and 
also on disease activity (clinical and/or radiologi-
cal) need confirmation over a longer observation 
time. Moreover, the mean age of our cohort was 
more than 40 years, and age is a well-known mod-
ulator of a therapy’s efficacy.31 Moreover, the pro-
pensity-score model cannot adjust for unexpected 
bias such as physicians’ recommendations in med-
ical treatment decisions.
In our study, the percentage of AEs was higher in 
the TRF group compared with the DMF group. 
Despite this, the proportion of SAEs leading to 
discontinuation of the study drug was similar 
between the two groups.
Figure 4. Reasons for withdrawal from the two study drug treatments during 12 months.
DMF, dimethyl fumarate; TRF, teriflunomide.
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The most commonly reported AEs for the DMF 
group included flushing, diarrhea, and abdominal 
pain. These findings are similar to previously 
reported data.13
pwRRMS treated with DMF in our study experi-
enced fewer SAEs than previously reported in 
registered trials in which 12% of patients who 
received DMF were found to have SAEs.7
In the DMF group in our study, lymphopenia 
was reported in five patients and necessitated 
discontinuation of the drug in two of them. 
Notably, the pwRRMS who discontinued ther-
apy for lymphopenia had a longer disease dura-
tion (mean of 12 years) and had received more 
than one prior therapy. These data suggest that 
certain individuals may have a poorer tolerabil-
ity of drugs, thus requiring multiple changes in 
DMTs in RRMS. We plan to further investi-
gate this possibility in extended follow-up 
studies.
The ENDORSE trial, an ongoing 12-year 
extension study of DEFINE/CONFIRM evalu-
ating the long-term safety, efficacy, and overall 
risk–benefit profile of DMF in patients with 
RRMS, maintains a favorable outlook on the 
long-term use of this drug despite the occur-
rence of AEs.26
In our study, the most commonly reported AEs 
associated with the use of TRF included elevated 
transaminases, alopecia, and increased blood 
pressure.
Recent reports on safety outcomes from up to 9 
years of treatment with TRF in an extension 
(NCT00803049) of the pivotal phase III 
Teriflunomide Multiple Sclerosis Oral (TEMSO) 
trial showed that approximately 11% of pwR-
RMS discontinued TRF treatment due to AEs. 
Around 20% of pwRRMS treated with this agent 
experienced SAEs. There were three deaths in the 
study, unrelated to TRF.8
Limitations of our study included the absence of 
blinding, which may have introduced detection 
and reporting bias. However, the follow-up pro-
tocols used in our study were largely comparable, 
and as such, the magnitude of such a bias is 
expected to be minimal. Although the data entry 
at our center typically occurs in real time or soon 
thereafter, some variables such as relapse-related 
information may be susceptible to recall bias. 
Finally, despite evidence showing the positive 
predictive value of NEDA 3 as a prognostic indi-
cator at 7 years, the accuracy of this data point as 
representative of true disease activity may be 
called into question by some.30
This study compared treatment outcomes over 
12 months and evaluated disability accumulation 
events over 6–12 months, which are highly indic-
ative of long-term disability outcomes.
Although the analyses of these observational 
data do not serve as a substitute for randomized 
clinical trials, our study does provide practical 
evidence representative of clinical care in tertiary 
MS centers and allows for valuable insights into 
the challenges of therapeutic management of 
RRMS.
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